Key Takeaways Exact Sciences unveiled Cancerguard, a new multi-cancer early detection blood test in the United States.EXAS' Cancerguard showed 64% sensitivity across cancers and 97.4% specificity to limit false positives.The company is enrolling 25,000 in the Falcon study to support coverage and future FDA submissions.Exact Sciences Corporation (EXAS) has launched the Cancerguard test, a new multi-cancer early detection (MCED) blood test now offered as a laboratory-developed test (LDT) in the United States. ...

Key Takeaways Exact Sciences is driving growth through Cologuard, Oncotype DX and new product launches.EXAS targets 15% revenue growth, $150M savings by 2026 and stronger operating margins.Macroeconomic pressures and fierce competition remain key challenges for Exact Sciences.Exact Sciences Corporation (EXAS) is well-poised to grow in the coming quarters, courtesy of the ongoing momentum in its Cologuard and Oncotype DX tests. The company continues to invest in its pipeline to develop innovative solutions f ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguardâ"¢ test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when treatm. ...

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team ...

Presentation[Audio Gap] diagnostics here at Baird. We're very excited to have Exact Sciences here with us today. From the company, we have the CEO, Kevin Conroy; CFO, Aaron Bloomer; and the new Chief Growth Officer, Raj Pudipeddi. So thanks, everyone, for joining us. And Kevin is going to kick us off with a few slides, and then we'll go into Q&A. If anyone has questions during the session, you can e-mail them to session1@rwbaird.com, and I will pass them along. Kevin?Kevin ConroyChairman of The Board & CEO ...

Presentation[Audio Gap] diagnostics here at Baird. We're very excited to have Exact Sciences here with us today. From the company, we have the CEO, Kevin Conroy; CFO, Aaron Bloomer; and the new Chief Growth Officer, Raj Pudipeddi. So thanks, everyone, for joining us. And Kevin is going to kick us off with a few slides, and then we'll go into Q&A. If anyone has questions during the session, you can e-mail them to session1@rwbaird.com, and I will pass them along. Kevin?Kevin ConroyChairman of The Board & CEO ...

Exact Sciences (NasdaqCM:EXAS) 2025 Conference September 09, 2025 10:50 AM ET Company ParticipantsRaj Pudipeddi - Chief Growth OfficerKevin Conroy - Chairman & CEOAaron Bloomer - CFOConference Call ParticipantsCatherine W. Ramsey Schulte - Senior Research AnalystCatherine W. Ramsey SchulteDiagnostics here at Baird. We're very excited to have Exact Sciences here with us today from the company. We have the CEO Kevin Conroy, CFO Aaron Bloomer, and the new Chief Growth Officer, Raj Pudapedi. Thanks everyone for ...

Question-and-Answer SessionBrandon CouillardWells Fargo Securities, LLC, Research Division Never short of things to talk about when it comes to Exact. We'll get to all those things. I do want to just kind of focus on maybe to start with fundamentals in 2Q, which were kind of overshadowed by Freenome from which we'll get to, of course, Cologuard growth accelerated for the second straight quarter, you're up like 18% year-over-year. Guide implies you kind of exit the year at a high teens clip. Cologuard Plus p ...

Exact Sciences (EXAS) FY 2025 Conference September 03, 2025 01:30 PM ET Company ParticipantsBrandon Couillard - Managing DirectorAaron Bloomer - CFOBrandon CouillardAll right. Good afternoon. Welcome to the Wells Fargo Healthcare Conference. I'm Brandon Couillard, cover Life Science Tools and Diagnostics. It is a real pleasure to have Exact Sciences back with us at the conference this year.Joining us for this conversation, CFO, Aaron Bloomer as well as Derek Lekow, our new Head of IR, in the audience. Aaron ...

Exact Sciences (EXAS) FY 2025 Conference September 03, 2025 01:30 PM ET Speaker0All right. Good afternoon. Welcome to the Wells Fargo Healthcare Conference. I'm Brandon Couillard, cover Life Science Tools and Diagnostics. It is a real pleasure to have Exact Sciences back with us at the conference this year.Joining us for this conversation, CFO, Aaron Bloomer as well as Derek Lekow, our new Head of IR, in the audience. Aaron, thanks for being here.Speaker1Thanks so much for having us. Great to be here.Speake ...